Sequoia Financial Advisors LLC Purchases Shares of 3,908 Teleflex Incorporated $TFX

Sequoia Financial Advisors LLC purchased a new stake in Teleflex Incorporated (NYSE:TFX) in the 2nd quarter, HoldingsChannel reports. The fund purchased 3,908 shares of the medical technology company’s stock, valued at approximately $462,000.

Several other large investors have also recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. increased its holdings in Teleflex by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,216,763 shares of the medical technology company’s stock valued at $859,095,000 after purchasing an additional 43,642 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Teleflex by 69.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company’s stock valued at $119,927,000 after purchasing an additional 355,720 shares in the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Teleflex by 122.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company’s stock valued at $80,784,000 after purchasing an additional 322,222 shares in the last quarter. TD Asset Management Inc increased its holdings in Teleflex by 0.7% in the 1st quarter. TD Asset Management Inc now owns 490,000 shares of the medical technology company’s stock valued at $67,713,000 after purchasing an additional 3,310 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Teleflex by 57.8% in the 1st quarter. Millennium Management LLC now owns 394,633 shares of the medical technology company’s stock valued at $54,534,000 after purchasing an additional 144,531 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Stock Up 1.8%

Shares of Teleflex stock opened at $130.42 on Tuesday. The business has a 50-day moving average of $125.38 and a 200-day moving average of $123.51. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The company has a market capitalization of $5.76 billion, a PE ratio of 30.69, a P/E/G ratio of 1.79 and a beta of 1.05. Teleflex Incorporated has a 1-year low of $108.90 and a 1-year high of $239.82.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business had revenue of $780.90 million for the quarter, compared to analysts’ expectations of $771.53 million. During the same quarter last year, the company posted $3.42 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, equities analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 15th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is presently 32.00%.

Insider Buying and Selling at Teleflex

In related news, CEO Liam Kelly purchased 1,500 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average price of $115.07 per share, with a total value of $172,605.00. Following the completion of the transaction, the chief executive officer owned 45,267 shares of the company’s stock, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gretchen R. Haggerty purchased 500 shares of Teleflex stock in a transaction dated Wednesday, August 6th. The shares were bought at an average cost of $114.75 per share, for a total transaction of $57,375.00. Following the transaction, the director directly owned 6,305 shares of the company’s stock, valued at approximately $723,498.75. The trade was a 8.61% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 5,500 shares of company stock valued at $633,590. Corporate insiders own 1.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TFX. Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Mizuho raised their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a report on Friday, August 1st. Zacks Research downgraded Teleflex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. Wells Fargo & Company lowered their target price on Teleflex from $137.00 to $131.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Teleflex in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.